Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

Trial Details

NCT ID
NCT06463028
Phase
PHASE2
Sponsor
Faeth Therapeutics
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Sapanisertib
  • Serabelisib
  • Paclitaxel
Locations (sample)
  • La Jolla, California, United States|32.84727,-117.2742
  • San Francisco, California, United States|37.77493,-122.41942
  • Miami Beach, Florida, United States|25.79065,-80.13005
  • St. Petersburg, Florida, United States|27.77086,-82.67927
  • West Palm Beach, Florida, United States|26.71534,-80.05337

Key Eligibility Criteria

  • Histologically confirmed diagnosis of endometrioid endometrial carcinoma.
  • Documented evidence of advanced or recurrent endometrial cancer that is not amenable to surgery/radiation for curative intent.
  • Participant has received at least 1 but not more than 4 prior systemic therapies. Prior therapy must include platinum-based chemotherapy and a chec…
  • PI3K/AKT/mTOR pathway gene alteration identified.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →